Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossoverCélèste Lebbé, Brigitte Dréno, Filippo de Braud et al.|Annals of Oncology|2016Cited by 14